accountaccounted for about 17 percent of Glaxos sales last year, compared with 18 percent for rivals New York-based Pfizer Inc. and 30 percent for Paris-based Sanofi-Aventis SA, according to data compiled by Bloomberg. Glaxo is trying delayed incentive plans to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Glaxo Faces ���War for Talent��� in Emerging-Market Race With Pfizer
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account